Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly making materially false and misleading statements regarding its business operations and compliance policies during the Class Period from November 30, 2023, to July 3, 2025 [8]. Allegation Details - The lawsuit claims that Jasper lacked necessary controls and procedures to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results and the regulatory prospects of its products, particularly briquilimab [3]. - The failure to maintain proper controls increased the likelihood of cost-reduction measures and overstated the company's business and financial prospects [3]. Next Steps - Investors who purchased Jasper shares and suffered losses are encouraged to contact the law firm for more information or to discuss their rights [4]. - There is no cost or obligation for investors to inquire about their claims [4]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across various courts [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jasper Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on November 18, 2025 [1] Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [3][6] - The lead plaintiff must file a motion with the court by November 18, 2025, to represent other class members [3] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4] Group 3: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false or misleading statements regarding its manufacturing controls and compliance with regulations, which could negatively impact its products' regulatory and commercial prospects [5] - Specific claims include the lack of necessary controls for third-party manufacturers, increased risk of confounded study results, and overstated business and financial prospects [5] - The lawsuit asserts that when the true details became known, investors suffered damages [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and lack of proper manufacturing controls [3][5]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in Jasper between November 30, 2023, and July 3, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Jasper, with a deadline of November 18, 2025, for investors to seek the role of lead plaintiff [3]. Group 2: Allegations Against Jasper - The complaint alleges that Jasper lacked necessary controls to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results and the commercial prospects of its products, including briquilimab [5]. - The company’s public statements were claimed to be materially false and misleading due to these failures [5]. Group 3: Stock Price Impact - Following a press release on July 7, 2025, which revealed issues with a drug product lot and subsequent halting of studies, Jasper's stock price fell by $3.73 per share, or 55.1%, closing at $3.04 per share [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by November 18, 2025 [1][3]. Company Overview - Jasper Therapeutics, Inc. is a publicly traded company on NASDAQ under the ticker JSPR [1]. - The company has faced significant challenges, including issues with third-party manufacturers and the integrity of clinical trial data [3][4]. Allegations and Issues - The complaint against Jasper alleges that the company lacked necessary controls to ensure compliance with current Good Manufacturing Practices (cGMP), which could confound clinical trial results [3]. - Specific concerns include the potential negative impact on the regulatory and commercial prospects of its product, briquilimab, and the likelihood of cost-reduction measures being implemented [3]. - Following a press release on July 7, 2025, Jasper's stock price fell by $3.73 per share, or 55.1%, closing at $3.04 per share due to the announcement of halted studies and restructuring plans [4]. Legal Proceedings - Investors who suffered losses between November 30, 2023, and July 3, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1][5]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [2].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jasper Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on November 18, 2025 [1]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm or visiting their website [3][6]. - The lead plaintiff must file a motion with the court by November 18, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in terms of settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing their capability in recovering funds for clients [4]. Group 3: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false and misleading statements regarding their manufacturing controls and compliance with regulations, which could negatively impact their product's prospects [5]. - Specific claims include the lack of necessary controls for third-party manufacturers, which increased risks related to clinical trial results and the overall business outlook for Jasper and its product briquilimab [5]. - The lawsuit asserts that these misrepresentations led to investor damages when the true information became public [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jasper Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on November 18, 2025 [1] Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [3][6] - The lead plaintiff must file a motion with the court by November 18, 2025, to represent other class members [3] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4] - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time [4] - Rosen Law Firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4] Group 3: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and compliance with regulations [5] - It is claimed that these failures increased the risk of negative outcomes in clinical trials and overstated the company's financial and business prospects [5] - The lawsuit asserts that when the true details became known, investors suffered damages due to the misleading public statements [5]

Core Viewpoint - Jasper Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading statements and failure to disclose material adverse facts regarding its business and clinical trials, particularly related to the briquilimab drug product [3]. Group 1: Company Developments - On July 7, 2025, Jasper announced issues with a drug product lot used in its BEACON Study for Chronic Spontaneous Urticaria, leading to a significant stock price drop of $3.73, or 55.1%, closing at $3.04 per share [2]. - The company is halting the development of briquilimab for asthma and SCID, and is implementing cost-cutting measures, including potential restructuring, to extend its financial runway [2]. Group 2: Lawsuit Details - The class action lawsuit alleges that Jasper's management made materially false and misleading statements and failed to disclose critical information about the company's operational controls and the risks associated with its clinical trials [3]. - Specific allegations include the lack of necessary controls for third-party manufacturers, which increased the risk of confounding study results and negatively impacted the company's regulatory and commercial prospects [3]. Group 3: Legal Actions - Investors who purchased Jasper securities during the class period from November 30, 2023, to July 3, 2025, have until November 18, 2025, to file a lead plaintiff motion in the class action lawsuit [1][4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by November 18, 2025 [1][3]. Company Overview - Jasper Therapeutics, Inc. is facing scrutiny for allegedly lacking necessary controls and procedures for third-party manufacturers, which may have impacted the integrity of clinical trials and the prospects of its products, particularly briquilimab [3]. Legal Allegations - The complaint against Jasper claims that the company made false or misleading statements regarding its manufacturing processes and the viability of its clinical trials, which could lead to overstated business and financial prospects [3]. - Specific allegations include the failure to ensure compliance with current Good Manufacturing Practices (cGMP), which increased the risk of confounded study results and potential cost-reduction measures [3]. Recent Developments - On July 7, 2025, Jasper reported issues with a drug product lot used in clinical trials, leading to a significant drop in stock price by $3.73 per share, or 55.1%, closing at $3.04 per share [4]. - The company announced a halt in the ETESIAN Study and paused development in asthma and SCID, contradicting previous statements about its financial stability and cash runway [4]. Investor Actions - Investors who suffered losses between November 30, 2023, and July 3, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][6]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Jasper's conduct [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jasper Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and compliance with cGMP regulations, which could negatively impact the clinical and commercial prospects of its products, including briquilimab [5]. - The failure to disclose these issues increased the risk of confounding results in ongoing studies and the likelihood of disruptive cost-reduction measures, leading to an overstatement of Jasper's business and financial prospects [5].

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly misleading investors regarding the commercial prospects of its lead product candidate, Briquilimab, during the period from November 30, 2023, to July 3, 2025 [1][2]. Allegations - The lawsuit claims that Jasper Therapeutics failed to disclose critical information, including: - Lack of necessary controls and procedures to ensure third-party manufacturers complied with cGMP regulations [2]. - Increased risk of confounding results in ongoing studies, negatively impacting regulatory and commercial prospects [2]. - Heightened likelihood of disruptive cost-reduction measures [2]. - Overstated business and financial prospects, as well as the clinical and commercial prospects of Briquilimab [2]. Stock Price Impact - Following the revelation of these issues on July 7, 2025, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decline, closing at $3.04 per share [3]. Class Action Participation - Shareholders may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiffs [4]. - Participation in the case is not required to be eligible for recovery, and shareholders can remain absent class members if they choose [4]. Firm Background - Robbins LLP is noted for its focus on shareholder rights litigation, helping shareholders recover losses and improve corporate governance since 2002 [5].